Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.

The post Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer appeared first on MedCity News.

Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.

The post Elli Lilly Cancer Drug Lands Its Second FDA Approval This Year appeared first on MedCity News.

Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.

The post Servier Gets First FDA Nod for Targeted Therapy in Rare Type of Blood Cancer appeared first on MedCity News.

FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.

The post FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class appeared first on MedCity News.

Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.

The post Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal appeared first on MedCity News.

Polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells, now has its first FDA-approved drug treatment. The agency awarded the regulatory nod to a PharmaEssentia drug that reduces the levels of those blood cells.

The post FDA approves PharmaEssentia interferon drug for a rare type of blood cancer appeared first on MedCity News.

The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.

The post Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders appeared first on MedCity News.

New York-based Stemline won Food and Drug Administration approval in December 2018 for Elzonris, a drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an extremely rare but aggressive form of leukemia.

The post Italy’s Menarini Group to acquire Stemline Therapeutics for $677M appeared first on MedCity News.

The companies will use Novo Nordisk’s experience with hemophilia and bluebird’s TALENs-based genome editing technology, megaTAL, with a particular focus on hemophilia A.

The post Novo Nordisk, bluebird bio partner on genome editing in hemophilia appeared first on MedCity News.

Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company’s technology and growth of its commercial use cases.

The post Personalized cancer treatment startup Notable Labs nabs $40M Series B appeared first on MedCity News.

In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.

The post Oncopeptides looks forward to updates on myeloma drug at European hematology conference appeared first on MedCity News.

Bispecific antibodies like Amgen’s AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies – which target the same antigen – be possible?

The post 2018 ASH meeting to feature new CAR-T therapies for myeloma appeared first on MedCity News.